Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 392 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension, Glaucoma, Open-Angle Clear all
Completed Phase 3 Interventional

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00314158
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension, Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension, Timolol 5 mg/ml eye drops, solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 11, 2026, 10:02 AM EDT
Terminated No phase listed Observational

Imaging Lens Deposits in Exfoliation Syndrome

NCT02042703
View directory record Official record
Conditions
Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
Interventions
anterior segment OCT
Device
Lead sponsor
Duke University
Other
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

NCT00947661
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0912, Reference0912
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT05335122
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
30
States / cities
Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 11, 2026, 10:02 AM EDT
Terminated Not applicable Interventional Results available

A Post-market Study Of Use Of The OMNI® Surgical System In Open Angle Glaucoma

NCT04616573
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
OMNI® Surgical System, iStent inject
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Dothan, Alabama • Vineland, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 11, 2026, 10:02 AM EDT
Terminated Not applicable Interventional

Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty

NCT02327312
View directory record Official record
Conditions
Primary Open-Angle Glaucoma
Interventions
Stents, Laser, Laser Trabeculoplasty
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
35 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Hemet, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 11, 2026, 10:02 AM EDT
Not yet recruiting Not applicable Interventional

A Prospective Interventional Cohort Study to Evaluate the Efficacy and Safety of the AquaLumen, a Novel Filtration Procedure for the Treatment of Open Angle Glaucoma

NCT06809647
View directory record Official record
Conditions
Glaucoma Open-Angle
Interventions
Glaucoma surgery
Device
Lead sponsor
PLU Ophthalmic
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Phase 3 Interventional

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

NCT00047515
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Alcon Investigational Agent
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Multiple Locations Throughout the United States, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 11, 2026, 10:02 AM EDT
Recruiting No phase listed Observational

Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis

NCT06953349
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis
Procedure
Lead sponsor
Barnet Dulaney Perkins Eye Centers
Network
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 11, 2026, 10:02 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

NCT06822738
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
XEN63 Glaucoma Treatment System
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Glendale, Arizona • Culver City, California • Petaluma, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 11, 2026, 10:02 AM EDT
Not listed Not applicable Interventional

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

NCT06313749
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Open Angle Glaucoma
Interventions
Minimally Invasive Micro Sclerostomy Device
Device
Lead sponsor
Sanoculis Ltd
Industry
Eligibility
40 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 11, 2026, 10:02 AM EDT
Active, not recruiting No phase listed Observational

Impact of Glaucoma and Visual Field Loss on Life Space

NCT03673644
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
Questionnaires
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 11, 2026, 10:02 AM EDT
Completed No phase listed Observational

Determinants of Compliance With Glaucoma Therapy

NCT01484392
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Not applicable Interventional Results available

Hydrus Microstent for Refractory Open-Angle Glaucoma

NCT03267134
View directory record Official record
Conditions
Open-angle Glaucoma
Interventions
Hydrus Microstent, Ophthalmic surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Fayetteville, Arkansas • Sacramento, California • Fort Collins, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Phase 4 Interventional

Lumigan Versus Cosopt

NCT00273455
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
bimatoprost 0.03%, dorzolamide 2%/timolol maleate 0.5% fixed combination, placebo
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Louisville, Kentucky • Mt. Pleasant, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 11, 2026, 10:02 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension

NCT06964191
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
Combination Product · Drug
Lead sponsor
PolyActiva Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 11, 2026, 10:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

NCT07780890
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG), Dry Eye Disease (DED), Keratoconus, Lasik Eye Surgery
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 79 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Not applicable Interventional Results available

The Effects of an Antioxidant Formulation on Ocular Blood Flow

NCT01930487
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
dietary supplement with antioxidants, Placebo
Dietary Supplement
Lead sponsor
ScienceBased Health
Industry
Eligibility
30 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Phase 3 Interventional

A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension

NCT00751127
View directory record Official record
Conditions
Glaucoma, Open Angle Glaucoma, Ocular Hypertension
Interventions
PhXA41, timolol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1994
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2011 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT02674854
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00651859
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
20 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Phase 3 Interventional

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

NCT00277498
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Xalacom, Xalatan, Timolol
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
64
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Artesia, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 11, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

24-hour Efficacy of AR-12286

NCT01330979
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-12286 0.5% Ophthalmic Solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 11, 2026, 10:02 AM EDT
Suspended Phase 3 Interventional

SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma

NCT00382395
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
SOLX Gold Shunt GMS-plus, Ahmed FP7 Glaucoma Valve
Device
Lead sponsor
SOLX, Inc.
Industry
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
9
States / cities
Petaluma, California • Littleton, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2015 · Synced Oct 11, 2026, 10:02 AM EDT